Dr Reddy’s Laboratories announced the launch of dimethyl fumarate delayed-release capsules, a therapeutic equivalent generic version of Tecfidera (dimethyl fumarate) delayed-release capsules, approved by the US Food and Drug Administration (USFDA).
The Tecfidera brand and generic market had US sales of approximately $3.8 billion MAT for the most recent twelve months ending in June 2020 according to IQVIA Health*.
These capsules are available in 120 mg and 240 mg capsules in bottle count sizes of 14 and 60 capsules, respectively.
The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.
